Xeris Biopharma Holdings
Stock Forecast, Prediction & Price Target
Xeris Biopharma Holdings (XERS) stock Price Target by analysts
$5.8
Potential downside: -20.77%
Xeris Biopharma Holdings price prediction
What is Xeris Biopharma Holdings stock analysts` prediction?
Xeris Biopharma Holdings stock forecast: Based on 2 Wall Street analysts` predicted price targets for Xeris Biopharma Holdings in the last 3 months, the avarage price target is $5.8, with a high forecast of $NaN. The average price target represents a -20.77% change from the last price of $7.32.
Disclaimer: This is not investment advice. Don't use price targets as the only investment indicator. Always remember to do your own thorough research and due diligence before making an investment decision.
Xeris Biopharma Holdings stock Price Target by analysts
Full breakdown of analysts given Xeris Biopharma Holdings price targets
| Analyst name & company | Analyst win rate | Publish date | Price target | Price when posted | Source | Historical targets |
|---|---|---|---|---|---|---|
Oren Livnat H.C. Wainwright | 0% 0/1 | 10 months ago | $6.6 -9.85% downside | $3.25 | StreetInsider | Previous targets (0) |
Leland Gershell Oppenheimer | 0% 0/1 | 11 months ago | $5 -31.70% downside | $3.02 | StreetInsider | Previous targets (0) |
David Amsellem Piper Sandler | 0% 0/1 | over 1 year ago | $3 -59.02% downside | $1.85 | StreetInsider | Previous targets (0) |
Unknown Craig-Hallum | N/A | over 3 years ago | $6.5 -11.21% downside | $2.33 | Benzinga | N/A |
Xeris Biopharma Holdings Financial Estimates
Xeris Biopharma Holdings Revenue Estimates
Xeris Biopharma Holdings EBITDA Estimates
Xeris Biopharma Holdings Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2016 | 12/31/2019 | 12/31/2022 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $1.07M N/A | $20.15M 1774.88% | $110.24M 447.00% | Avg: $220.35M Low: $196.49M High: $233.54M avg. 99.87% | Avg: $262.68M Low: $241.37M High: $274.21M avg. 19.20% | Avg: $308.04M Low: $283.06M High: $321.57M avg. 17.26% | Avg: $356.94M Low: $327.98M High: $372.61M avg. 15.87% |
Net Income
% change YoY
| $-13.20M N/A | $-91.14M -589.98% | $-94.66M -3.86% | Avg: $-31.46M Low: $-55.06M High: $-11.01M avg. 66.75% | Avg: $10.87M Low: $-6.88M High: $26.15M avg. 134.56% | Avg: $45.43M Low: $40.64M High: $48.02M avg. 317.75% | Avg: $72.96M Low: $65.27M High: $77.13M avg. 60.60% |
EBITDA
% change YoY
| $-13.09M N/A | $-117.79M -799.83% | $-69.31M 41.15% | Avg: $-153.28M Low: $-162.45M High: $-136.68M avg. -121.13% | Avg: $-182.72M Low: $-190.74M High: $-167.90M avg. -19.20% | Avg: $-214.27M Low: $-223.68M High: $-196.89M avg. -17.26% | Avg: $-248.28M Low: $-259.18M High: $-228.14M avg. -15.87% |
EPS
% change YoY
| -$7.17 N/A | -$3.49 51.32% | -$0.7 79.94% | Avg: -$0.21 Low: -$0.4 High: -$0.08 avg. 69.52% | Avg: $0.06 Low: -$0.05 High: $0.19 avg. 129.06% | Avg: $0.33 Low: $0.3 High: $0.35 avg. 432.25% | Avg: $0.53 Low: $0.47 High: $0.56 avg. 60.60% |
Operating Expenses
% change YoY
| $14.29M N/A | $94.37M 560.04% | $169.55M 79.66% | Avg: $422.36M Low: $376.63M High: $447.64M avg. 149.10% | Avg: $503.49M Low: $462.65M High: $525.59M avg. 19.20% | Avg: $590.43M Low: $542.54M High: $616.36M avg. 17.26% | Avg: $684.15M Low: $628.65M High: $714.18M avg. 15.87% |
FAQ
What is Xeris Biopharma Holdings stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 144.91% in 2025-2028.
We have gathered data from 6 analysts. Their low estimate is -55.06M, average is -31.46M and high is -11.01M.
What is Xeris Biopharma Holdings stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 38.05% in 2025-2028.
We have gathered data from 6 analysts. Their low revenue estimate is $196.49M, average is $220.35M and high is $233.54M.
What is Xeris Biopharma Holdings stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 172.86% in 2025-2028.
We have gathered data from 6 analysts. Their low earnings per share estimate is -$0.4, average is -$0.21 and high is $-0.08.
What is the best performing analyst?
In the last twelve months 2 analysts have been covering Xeris Biopharma Holdings stock. The most successful analyst is Oren Livnat.